Aug 26, 2019
Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women
Aug 13, 2019
New Research Identifies How Microbiome Can Increase Risk or Protection Against Sexually Transmitted Infections (STIs)
May 23, 2019
FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea
Apr 23, 2019
Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
Nov 07, 2018
Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 03, 2018
Evofem Biosciences to Present Data on Methodology and Current Status of Two Ongoing Clinical Studies of Amphora at the 2018 International Federation of Gynecology and Obstetrics (FIGO) World Congress
Sep 21, 2018
New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine (ASRM) Annual Congress
Aug 23, 2018
Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018
Aug 02, 2018
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Apr 16, 2018
Roche receives FDA clearance for cobas® CT/NG for cobas® 6800/8800 Systems
Jan 23, 2018
Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019